Publications by authors named "O Mosenzon"
Chronic kidney disease (CKD) affects approximately 13% of people globally, including 20%-48% with type 2 diabetes (T2D), resulting in significant morbidity, mortality, and healthcare costs. There is an urgent need to increase early screening and intervention for CKD. We are experts in diabetology and nephrology in Central Europe and Israel.
View Article and Find Full Text PDFAim: To assess the association between urinary albumin-to-creatinine ratio (UACR) categories within the normal range with mortality and adverse cardiovascular outcomes.
Materials And Methods: PubMed and Embase were systematically searched for real-world evidence studies. Studies were manually evaluated according to predefined eligibility criteria.
Background: Chronic kidney disease (CKD) has a global prevalence of 9.1-13.4%.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to create a risk assessment tool for identifying type 2 diabetes (T2D) patients at higher risk of kidney disease progression, focusing on those who may benefit from SGLT2 inhibitors like dapagliflozin.
- The research analyzed data from over 41,000 T2D patients, identifying eight key predictors of kidney disease progression and validating the model, showing strong predictive accuracy.
- Results indicated that while dapagliflozin's relative risk reduction was consistent across risk categories, patients with higher baseline risk experienced a greater absolute reduction in kidney disease progression over time.